| Literature DB >> 30036647 |
Daniel Apel1, Michele Brunelli2, Mohammed El-Gahry3, J Christoph Geller2, Bernward Lauer3, Marc-Alexander Ohlow3.
Abstract
AIMS: The aim of this study was to analyze whether local application of 3% hydrogen peroxide (H2O2) additionally to standard antibiotic prophylaxis following implantation of cardiac implantable electronic devices (CIED) reduces the incidence of pocket infections (PI).Entities:
Keywords: Defibrillator; Hydrogen peroxide; Implantation; Pacemaker; Pocket infection; Prevention
Year: 2018 PMID: 30036647 PMCID: PMC6160520 DOI: 10.1016/j.ipej.2018.07.004
Source DB: PubMed Journal: Indian Pacing Electrophysiol J ISSN: 0972-6292
Data given as n (%). The table represents all cases of each implanting physician. regardless whether H2O2 was used or not. There was no significant difference in the incidence of PI between each physician.
| Incidence of pocket infection related to the implanting physician | ||
|---|---|---|
| Cases with Pocket Infection (n = 23) | Cases without Pocket Infection (n = 1.287) | |
| Physician 1 | 5 (1.5%) | 324 |
| Physician 2 | 0 (0.0%) | 91 |
| Physician 3 | 7 (2.3%) | 305 |
| Physician 4 | 6 (2.0%) | 297 |
| Physician 5 | 0 (0.0%) | 34 |
| Physician 6 | 0 (0.0%) | 31 |
| Physician 7 | 5 (2.9%) | 175 |
| Physician 8 | 0 (0.0%) | 30 |
Data given as mean ± SD or n (%).* Significant value. BMI (body mass index). CABG (coronary artery bypass grafting). CRP (C-reactive protein). INR (international normalized ratio). PCI (percutaneous coronary intervention).
| Clinical Baseline Characteristics | |||
|---|---|---|---|
| H2O2-group (n = 429) | Control-group (n = 858) | p-Value | |
| Age [years] | 69 ± 12 | 69 ± 12 | case-control matching characteristics |
| Sex [male] | 289 (67.4%) | 578 (67.4%) | |
| BMI [kg/m2] | 28 ± 4.0 | 28 ± 4.0 | |
| Procedure Time [min] | 45 ± 23 | 45 ± 23 | |
| Medical History | |||
| Dilative Cardiomyopathy | 100 (23.3%) | 182 (21.2%) | 0.39 |
| Coronary Heart Disease | 233 (54.3%) | 448 (52.2%) | 0.51 |
| Prior CABG | 96 (22.4%) | 180 (21.0%) | 0.72 |
| Prior PCI | 176 (41.0%) | 339 (33.5%) | 0.63 |
| Hypertension | 357 (83.2%) | 736 (85.7%) | 0.25 |
| Diabetes | 172 (40.1%) | 324 (37.8%) | 0.43 |
| Chronic Kidney Disease | 126 (29.4%) | 271 (31.6%) | 0.44 |
| Echocardiographic Findings | |||
| Ejection Fraction [%] | 40 ± 15 | 43 ± 16 | 0.90 |
| Current Medication | |||
| Single-Platelet-Inhibition | 117 (27.3%) | 274 (31.9%) | 0.09 |
| Dual-Platelet-Inhibition | 108 (25.2%) | 170 (19.8%) | 0.03* |
| Anticoagulation | 166 (38.7%) | 300 (34.9%) | 0.20 |
| Laboratory Values | |||
| CRP [mg/l] | 12.9 ± 24.1 | 12.4 ± 22.4 | 0.98 |
| Leucocytes [×10³/μl] | 8.0 ± 2.5 | 7.9 ± 2.9 | 0.98 |
| Platelets [×10³/μl] | 216 ± 79 | 216 ± 100 | 1.00 |
| INR | 1.3 ± 0.49 | 1.3 ± 0.44 | 1.00 |
Data given as number or mean ± SD (%).* Significant value. CRT (cardiac resynchronization therapy).
| Procedural Characteristics | |||
|---|---|---|---|
| H2O2-group (n = 429) | Control-group (n = 858) | P-value | |
| Heart Rhythm Device | |||
| Pacemaker [PM] | 197 (45.9%) | 409 (47.7%) | 0.59 |
| Single Chamber PM | 23 (5.4%) | 60 (7.0%) | 0.28 |
| Dual Chamber PM | 122 (28.4%) | 292 (34.0%) | 0.04* |
| CRT-PM | 52 (12.1%) | 57 (6.6%) | <0.01* |
| Implantable-Cardioverter-Defibrillator [ICD] | 230 (53.6%) | 397 (46.3%) | 0.01* |
| Single Chamber ICD | 61 (14.2%) | 167 (19.5%) | 0.02* |
| Dual Chamber ICD | 31 (7.2%) | 57 (6.6%) | 0.72 |
| CRT-D | 138 (32.2%) | 173 (20.2%) | <0.01* |
| Implantable-Loop-Recorder | 2 (0.5%) | 43 (5%) | <0.01* |
| Cardiac Contractility Modulation | 0% | 9 (1.0%) | – |
| Temporary Pacing | |||
| Prior temporary pacing | 53 (12.7%) | 83 (9.7%) | 0.15 |
| Duration [days] | 2.9 ± 1.8 | 3.3 ± 3.0 | 0.92 |
| Implantation Procedure | |||
| 1st Procedure | 252 (58.7%) | 538 (62.7%) | 0.18 |
| Follow-Up Intervention | 177 (41.3%) | 320 (37.3%) | 0.18 |
| Generator exchange | 29 (6.8%) | 104 (12.1%) | <0.01* |
| Device upgrade | 84 (19.6%) | 90 (10.5%) | <0.01* |
| Device explantation | 17 (4.0%) | 35 (4.1%) | 1.0 |
| Complications needing revision | 47 (11.0%) | 91 (10.6) | 0.84 |
| Lead dysfunction | 35 (8.2%) | 78 (9.1%) | 0.60 |
| Pocket Hematoma | 6 (1.4%) | 16 (1.9%) | 0.65 |
| Device Placement | |||
| Site of operation [left] | 367 (85.5%) | 740 (86.2%) | 0.73 |
| Sub-cutaneous/sub-fascial | 392 (91.4%) | 757 (88.2%) | 0.13 |
| Sub-muscular | 36 (8.4%) | 97 (11.3%) | 0.12 |
| Venous Access | |||
| Puncture (subclavian/axillary vein) | 378 (88.1%) | 667 (77.7%) | <0.01* |
| Cephalic cut-down | 5 (1.2%) | 8 (0.9%) | 0.77 |
| Wound Closure | |||
| Intracutaneous suture | 21 (4.9%) | 189 (22.0%) | <0.01* |
| Dermal Glue | 408 (95.1%) | 669 (77.9%) | <0.01* |
| Bleeding Management | |||
| Drainage | 50 (11.7%) | 117 (13.6%) | 0.33 |
| D-stat Flowable Hemostat™ | 39 (9.1%) | 30 (3.5%) | <0.01* |
Fig. 2Pocket infection free survival in “H2O2-group” (grey lined) and “Control-group” (black lined). Hazard Ratio (HR). Confidence interval (CI).
All cases of pocket infections are shown. In two cases no bacteria could be identified but pocket infection seems to be very likely in the presence of purulent discharge. CRP (C-reactive protein. Staph. (Staphylococcus).
| Pocket Infection Related Characteristics | ||||||
|---|---|---|---|---|---|---|
| N | Bacteria | Fever [≥38 °C] | CRP [mg/l] | Leucocytes [x103/μL] | Lead affected | Signs of infection |
| 1 | Staph. epidermidis | – | 24.0 | 6.4 | – | purulent discharge. tenderness |
| 2 | Staph. aureus | Yes | 129.0 | 7.9 | – | erythema |
| 3 | – | 12.7 | 9.2 | Yes | – | |
| 4 | Staph. epidermidis | – | 37.7 | 4.5 | – | tenderness |
| 5 | Staph. aureus | – | 44.0 | 7.6 | – | erythema |
| 6 | Staph. epidermidis | – | 32.5 | 21.9 | – | purulent discharge |
| 7 | Staph. epidermidis | Yes | 17.8 | 14.5 | Yes | erythema |
| 8 | Staph. epidermidis | 1.4 | 3.9 | – | erythema. | |
| 9 | Staph. epidermidis | Yes | 237.0 | 18.3 | – | tenderness |
| 10 | – | – | 99.3 | 9.4 | – | purulent discharge. tenderness. erythema |
| 11 | Actinomyces viscosus | – | 4.3 | 8.7 | – | tenderness |
| 12 | Staph. aureus | Yes | 316.0 | 3.3 | – | purulent discharge. erythema. tenderness |
| 13 | Staph. aureus | – | 13.3 | 7.9 | – | purulent discharge. erythema. tenderness |
| 14 | Staph. epidermidis | – | 15.9 | 8.2 | – | purulent discharge. erythema. tenderness |
| 15 | Staph. aureus | Yes | 129.0 | 7.9 | – | serous discharge. erythema |
| 16 | Staph. aureus | Yes | 158.5 | 11.5 | Yes | purulent discharge. erythema |
| 17 | Staph. aureus | – | 3.8 | 7.4 | – | purulent discharge. erythema |
| 18 | – | – | 1.6 | 6.4 | – | purulent discharge |
| 19 | Staph. epidermidis | Yes | 22.7 | 10.6 | – | purulent discharge. erythema |
| 20 | Gemella morbillorum | – | 119.3 | 7.0 | – | tenderness |
| 21 | Staph. epidermidis | – | 22.9 | 8.8 | – | purulent discharge |
| 22 | Staph. epidermidis | – | 5.2 | 8.1 | – | purulent discharge |
| 23 | Staph. aureus | Yes | 366.0 | 5.7 | – | purulent discharge |
Fig. 1The number of pocket infections is presented in a time dependent manner. Black columns indicate infections of the control group. White columns indicate infections of the cases group.